Phase 2 Lymphoma Trial, Recruiting NCT06533579 Sponsor: Vironexis Biotherapeutics Inc. Condition: Lymphoma
Back to Lymphoma

Phase 2 Lymphoma Trial, Recruiting

NCT06533579
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • In Part 1 of the trial, you must be between 18 and 90 years old; in Part 2, you must be between 13 and 90 years old
  • You have been diagnosed with leukemia or lymphoma that has come back after treatment or has not responded to treatment, as defined by the trial's specific guidelines
  • Your cancer cells must test positive for a protein called CD19
  • You must have a low enough level of antibodies to a specific virus used in the treatment (called AAV) in your blood (confirm with trial site)
  • Your kidneys, liver, heart, and lungs must be functioning within the ranges required by the trial
  • Your blood cell counts and related measurements must fall within the ranges required by the trial

Who may not be able to join:

  • You have signs of liver stress, shown by elevated levels of certain liver enzymes in your blood (confirm with trial site)
  • You have a history of a blood vessel disorder called thrombotic microangiopathy, a heart muscle disease called cardiomyopathy, or you currently have problems with nerve sensitivity or sensation
  • You are currently pregnant or breastfeeding
  • You have moderate to severe acute Graft versus Host Disease (a complication sometimes seen after transplants), or any level of chronic Graft versus Host Disease
  • You have a history of being allergic to steroid medications, or have had serious side effects from them in the past
  • You have received chemotherapy too recently before joining the trial, within timeframes set out by the trial guidelines

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 6 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Vironexis Clinical Trials, Vironexis Biotherapeutics Inc.

Phone: 908-938-6019

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Vironexis Biotherapeutics Inc.
Registry
ClinicalTrials.gov
Start date
30 May 2025
Est. completion
1 June 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Treatment emergent adverse events (TEAEs) and treatment-emergent serious events (TESAEs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov